NCDs vs LCDs: How Medicare Coverage Determinations Work for Device Companies

2026-09-20 · Caduvo Team

Understand how Medicare makes coverage decisions through NCDs and LCDs, how MACs evaluate medical devices, and how to navigate restrictive policies.

An FDA clearance or approval does not obligate Medicare to pay for a medical technology. While the FDA evaluates safety and effectiveness, the Centers for Medicare & Medicaid Services (CMS) and its regional contractors operate under an entirely different statutory mandate: determining whether an item or service is "reasonable and necessary" for Medicare beneficiaries under Section 1862(a)(1)(A) of the Social Security Act. For market access teams, commercial viability depends on whether Medicare evaluates your technology nationally or regionally, and whether an active policy restricts its clinical use.

Understanding the mechanics of a national coverage determination versus a local coverage determination dictates your clinical trial endpoints, evidence planning, and commercial timeline. Comparing an ncd vs lcd reveals fundamental differences in scope, authority, and appeals. Here is how Medicare establishes coverage policy, how regional contractors exercise discretion, and how to address coverage when policies are absent or restrictive.

The Coverage Hierarchy: NCD vs LCD

Medicare coverage decisions exist within a strict statutory hierarchy governed by the Social Security Act. Before an item can be covered, it must satisfy three criteria outlined in CMS statutory criteria for Medicare coverage: it must fall within a statutorily defined benefit category under Section 1861, it cannot be specifically excluded by statute (such as hearing aids or cosmetic surgery under Section 1862(a) or 42 CFR Part 411, Subpart A), and it must be reasonable and necessary under Section 1862(a)(1)(A).

A national coverage determination (NCD) is an administrative decision issued directly by CMS that dictates how Medicare covers or excludes an item or service nationally. When CMS issues an NCD, that policy binds all Medicare Administrative Contractors (MACs), Qualified Independent Contractors (QICs), administrative law judges (ALJs), attorney adjudicators, and the Medicare Appeals Council within the Department of Health and Human Services. However, an NCD addresses only clinical coverage. It does not determine coding assignments or establish payment dollar amounts—those functions require separate mechanisms within the broader medical device reimbursement framework.

A local coverage determination (LCD) is a regional policy issued by an individual MAC under Section 1869(f)(2)(B) of the Act. An LCD governs coverage exclusively within that contractor's multi-state jurisdiction. Under Section 1862(l)(5), MACs have statutory authority to develop an LCD in the absence of an NCD, or to supplement an NCD as long as the LCD policy does not conflict with national policy. Most Medicare coverage decisions are made locally by the MACs rather than by CMS central staff.

How MACs Set Policy and the LCD Development Process

Medicare relies on private health insurers operating as MACs to process Part A and Part B claims across designated jurisdictions. Regional contractors include A/B MACs like Novitas Solutions, Noridian Healthcare Solutions, Palmetto GBA, CGS Administrators, and First Coast Service Options, alongside specialized DME MACs (such as JA, JC, and JD) listed in CMS contractor directory tables.

When a device enters commercial distribution, the relevant MAC can decide coverage on a claim-by-claim basis or initiate a formal local coverage determination. Device manufacturers, clinicians, or beneficiaries residing in or doing business in the MAC's jurisdiction can also formally request an LCD. Under Chapter 13 of the Medicare Program Integrity Manual (PIM), a formal LCD request must satisfy specific administrative criteria, as detailed in the CMS local coverage determination timeline:

Once a complete request arrives, the MAC reviews the submission within 60 calendar days and notifies the requestor whether the request is complete. If complete, the MAC starts the development process under PIM Chapter 13, Section 13.2. During this process, the MAC has discretion to consult with subject matter experts and the CAC. The CAC provides a formal mechanism for healthcare professionals to review the evidence used in developing the LCD and promotes communication between the MAC and the healthcare community. CAC members are typically physicians, beneficiary representatives, or representatives of medical specialty organizations.

After completing reviews and consultations, the MAC posts a Proposed LCD on the Medicare Coverage Database (MCD). Proposed LCD document IDs begin with the letters "DL" (such as DL33797 for topical oxygen therapy or DL33317 for silicone external breast prostheses). Under PIM Chapter 13, MACs generally have 365 days from the publication date of the proposed LCD to finalize or retire the policy.

Finalized LCDs receive an "L" document ID (such as L12345) and contain clinical indications and limitations of coverage. MACs separate clinical policy from billing rules. Specific billing instructions, HCPCS modifier rules, revenue codes, and bill types appear in companion Billing and Coding Articles rather than the LCD itself. If you are examining coverage for a specific code pair, our review of HCPCS vs CPT codes explains how procedural and device codes are classified before being mapped into these local articles.

Researching the Medicare Coverage Database

Market access teams must inspect the Medicare Coverage Database to assess competitor policies and monitor draft decisions. The MCD is the central federal repository maintained by CMS for both national and regional Medicare determinations.

According to the CMS manual on using the Medicare Coverage Database, national and local documents follow distinct update cycles:

When searching the database, differentiate between the core document types defined in CMS coverage document type guidance:

  1. Proposed LCDs (DL-prefix): Draft policies undergoing review. The LCD Tracking Sheet—introduced for Proposed LCDs published after January 1, 2022—displays the issue summary, requestor details, key document links, process dates, and historical considerations.
  2. Final LCDs (L-prefix): Active regional coverage policies outlining medical necessity criteria.
  3. Billing and Coding Articles: Companion documents that directly support an LCD (LCD Reference Articles). They include CPT/HCPCS procedure codes, ICD-10-CM diagnosis codes, bill types, revenue codes, and modifier codes to assist providers with correct claims submission.
  4. Non-LCD Articles: Standalone administrative guidance issued by contractors that does not link to an LCD, such as Self-Administered Drug (SAD) Exclusion List Articles.

Caduvo monitors these weekly Thursday MCD database refreshes, alerting teams when contractors open draft coverage policies or alter coding articles within target disease states.

Managing Absent or Restrictive Medicare Coverage

When evaluating a new device, device teams encounter one of three coverage scenarios: a coverage vacuum, an overly restrictive LCD, or a prohibitive national policy. Each requires a distinct operational strategy.

1. The Coverage Vacuum: Case-by-Case Adjudication

When no NCD and no LCD exist for a new procedure or technology, Medicare coverage defaults to claim-by-claim adjudication by regional MACs. The MAC evaluates claims directly against the reasonable and necessary standard of Section 1862(a)(1)(A). Commercial success depends on providing ordering physicians with rigorous medical-record documentation: objective diagnostic results, documented failure of conservative treatments, and complete operative notes.

For outpatient DMEPOS technologies, manufacturers can request a preliminary Benefit Category Determination (BCD) directly from CMS via email to DMEPOS@cms.hhs.gov, independent of any HCPCS coding request, under the public consultation process outlined in CMS coverage guidelines. For Part B supplier payment context, see our analysis of the Medicare DME fee schedule.

2. Restrictive Local Coverage: Public Participation and CAC Engagement

If a MAC issues a proposed LCD containing restrictive indications or classifying a technology category as not reasonable and necessary, market access teams must mobilize during the public comment period and open meetings that follow the proposed LCD's release. Submit complete clinical dossiers containing peer-reviewed, published clinical evidence during the 365-day finalization window.

If an LCD is already finalized, an interested party doing business in that MAC's jurisdiction can submit a formal written request for revisions under PIM Chapter 13. The request must include full copies of published peer-reviewed evidence, justify the statutory benefit category, and propose specific coverage wording.

3. National Policy: Pursuing or Reconsidering an NCD

Requesting an NCD is a high-stakes strategy. An affirmative national coverage determination creates uniform access across all 50 states, but a national non-coverage decision forecloses coverage at every MAC across the country.

Under Section 1862(l) of the Act and the Federal Register notice published August 7, 2013 (78 FR 48164-69), CMS follows a rigid timeline for NCD requests, detailed in CMS national coverage determination process requirements:

If seeking to revise an existing NCD, CMS accepts reconsideration requests if the requester presents additional scientific evidence not considered during the most recent review, or plausible arguments that CMS materially misinterpreted existing evidence when the NCD was decided. Under the 2013 Federal Register rule, CMS also established an expedited administrative process to remove certain NCDs older than 10 years since their most recent review, returning coverage discretion to regional MACs under the Act.

Actionable Steps for Device Teams

  1. Confirm the Statutory Benefit Category First: Before assessing clinical trial design, verify under Section 1861 that your device fits into a recognized Medicare benefit category (such as DME, prosthetic devices, or physician services). Without a statutory category, neither CMS nor a MAC has authority to cover the technology.
  2. Audit Both LCDs and Billing Articles: Do not rely solely on the medical necessity text of an LCD (L-prefix). Always inspect the companion Billing and Coding Article to confirm which CPT, HCPCS, and ICD-10-CM diagnosis codes support payment.
  3. Map Regional MAC Jurisdictions: Cross-reference your target clinical sites against the MAC jurisdictions (such as Noridian, Novitas, Palmetto, or CGS). Prioritize engagement in the specific jurisdictions where your commercial accounts operate before petitioning CMS nationally.
  4. Track the Weekly Thursday MCD Update: Monitor proposed LCDs (DL-prefix) and LCD Tracking Sheets weekly. Participating in public meetings and submitting full-text evidence while a proposed LCD is active is your primary avenue to influence coverage language before the contractor finalizes the policy.

Sources

  1. Medicare Coverage Determination Process | CMS
  2. Medicare Coverage of Items and Services | CMS
  3. Local Coverage Determinations | CMS
  4. Medicare Coverage Document Type Descriptions
  5. Local Coverage Determination Process and Timeline | CMS
  6. How to Use the Medicare Coverage Database

General information, not regulatory, legal or reimbursement advice. Company and product names belong to their owners; a mention does not imply affiliation or endorsement. Report an error. Data and corrections policy.

Related reading